Page last updated: 2024-10-15
acetylcarnitine and Androgen-Independent Prostatic Cancer
acetylcarnitine has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG)." | 2.78 | A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013) |
| "Methods." | 2.78 | A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Campone, M | 1 |
| Berton-Rigaud, D | 1 |
| Joly-Lobbedez, F | 1 |
| Baurain, JF | 1 |
| Rolland, F | 1 |
| Stenzl, A | 1 |
| Fabbro, M | 1 |
| van Dijk, M | 1 |
| Pinkert, J | 1 |
| Schmelter, T | 1 |
| de Bont, N | 1 |
| Pautier, P | 1 |
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy： A Randomized, Controlled, Open-label, Phase 2 Trail[NCT05601479] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-11-01 | Not yet recruiting |
| Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone[NCT00468481] | Phase 3 | 385 participants (Actual) | Interventional | 2007-04-30 | Completed |
| (REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.[NCT00751205] | Phase 2 | 150 participants (Actual) | Interventional | 2008-08-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Mean Change From Baseline in Plasma Folate Levels at Week 12
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 12
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 17.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0.3 |
Mean Change From Baseline in Plasma Folate Levels at Week 16
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 16
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 17.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 2.4 |
Mean Change From Baseline in Plasma Folate Levels at Week 20
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 20
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 15.1 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -1.6 |
Mean Change From Baseline in Plasma Folate Levels at Week 4
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 4
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 15.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0.6 |
Mean Change From Baseline in Plasma Folate Levels at Week 8
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 8
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 18.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 2.2 |
Mean Change From Baseline in Plasma Homocysteine Levels at Week 12
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 12
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0 |
Mean Change From Baseline in Plasma Homocysteine Levels at Week 16
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 16
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -0.1 |
Mean Change From Baseline in Plasma Homocysteine Levels at Week 20
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 20
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -0.2 |
Mean Change From Baseline in Plasma Homocysteine Levels at Week 24
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 24
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0.1 |
Mean Change From Baseline in Plasma Homocysteine Levels at Week 4
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 4
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 0 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0 |
Mean Change From Baseline in Plasma Homocysteine Levels at Week 8
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 8
| Intervention | µg/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0 |
Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 12
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 405.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 86.5 |
Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 16
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 448.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 68.0 |
Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 20
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 452.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 64.6 |
Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 4
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 110.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -37.6 |
Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 8
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 310.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 68.2 |
Mean Neural Tube Defect (NTD) Risk Reduction at Week 24
The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline (NCT00468481)
Timeframe: Baseline and week 24
| Intervention | per 1000 birth (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.51 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -0.03 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 50.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 47.1 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 67.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 46.4 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 67.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 51.8 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 61.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 45.9 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 64.0 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 43.7 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 60.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 45.9 |
Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 68.1 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 54.1 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 41.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 41.5 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 42.3 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 43.2 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 39.7 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 58.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 39.8 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 43.1 |
Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 60.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 41.8 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1122.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1345.0 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1469.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1378.4 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1460.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1454.7 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1486.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1435.9 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1500.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1316.1 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1175.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1256.1 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1412.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1407.6 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 910.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 915.1 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1308.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1025.2 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1365.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 967.6 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1419.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 981.3 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1355.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 949.2 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1007.1 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 889.5 |
Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1184.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 970.4 |
Plasma Folate Level at 24 Weeks
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 60.55 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 41.67 |
Red Blood Cell (RBC) Folate Level at 24 Weeks
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1406.91 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1022.21 |
Trials
1 trial available for acetylcarnitine and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.The oncologist, 2013, Volume: 18, Issue:11
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |